165 related articles for article (PubMed ID: 18761739)
1. Ampullary adenocarcinoma - differentiation matters.
Schirmacher P; Büchler MW
BMC Cancer; 2008 Sep; 8():251. PubMed ID: 18761739
[TBL] [Abstract][Full Text] [Related]
2. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater.
Ang DC; Shia J; Tang LH; Katabi N; Klimstra DS
Am J Surg Pathol; 2014 Oct; 38(10):1371-9. PubMed ID: 24832159
[TBL] [Abstract][Full Text] [Related]
3. Ampullary cancer--a separate clinical entity?
Perysinakis I; Margaris I; Kouraklis G
Histopathology; 2014 May; 64(6):759-68. PubMed ID: 24456259
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the two histological subtypes of ampullary adenocarcinoma: a retrospective study.
Xu ZY; Guan J; Zhang ZY; Liu DW; Li XD; Zhou ZQ
Cir Cir; 2024; 92(2):159-164. PubMed ID: 38782386
[TBL] [Abstract][Full Text] [Related]
5. Role of Immunohistochemistry in the Subtyping of Periampullary Adenocarcinoma.
Bakshi N; Dhawan S; Nundy S; Rao S; Chopra P; Bhalla S
Int J Surg Pathol; 2019 Sep; 27(6):598-608. PubMed ID: 30942099
[No Abstract] [Full Text] [Related]
6. [Tumors of Vater's ampulla].
Gassler N; Knüchel R
Pathologe; 2012 Feb; 33(1):17-23. PubMed ID: 22293786
[TBL] [Abstract][Full Text] [Related]
7. Differentiation and prognostic markers in ampullary cancer: Role of p53, MDM2, CDX2, mucins and cytokeratins.
Perysinakis I; Minaidou E; Mantas D; Sotiropoulos GC; Leontara V; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Pathol Res Pract; 2016 Nov; 212(11):1039-1047. PubMed ID: 27688085
[TBL] [Abstract][Full Text] [Related]
8. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma.
Overman MJ; Soifer HS; Schueneman AJ; Ensor J; Adsay V; Saka B; Neishaboori N; Wolff RA; Wang H; Schnabel CA; Varadhachary G
BMC Cancer; 2016 Aug; 16(1):668. PubMed ID: 27549176
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of Ampullary Adenocarcinoma].
Shin DW
Korean J Gastroenterol; 2023 Oct; 82(4):159-170. PubMed ID: 37876255
[TBL] [Abstract][Full Text] [Related]
10. The use of histopathological subtyping in patients with ampullary cancer: a nationwide analysis.
de Bakker J; Sommeijer D; Besselink M; Kazemier G; van Grieken N
World J Surg Oncol; 2022 Dec; 20(1):406. PubMed ID: 36566267
[TBL] [Abstract][Full Text] [Related]
11. Approaches to Biopsy and Resection Specimens from the Ampulla.
Xue Y; Reid MD
Surg Pathol Clin; 2020 Sep; 13(3):453-467. PubMed ID: 32773194
[TBL] [Abstract][Full Text] [Related]
12. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?
Westgaard A; Pomianowska E; Clausen OP; Gladhaug IP
Ann Surg Oncol; 2013 Feb; 20(2):430-9. PubMed ID: 22956064
[TBL] [Abstract][Full Text] [Related]
13. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma.
Zimmermann C; Wolk S; Aust DE; Meier F; Saeger HD; Ehehalt F; Weitz J; Welsch T; Distler M
Sci Rep; 2019 Sep; 9(1):12676. PubMed ID: 31481741
[TBL] [Abstract][Full Text] [Related]
14. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
15. MRCP and ERCP to detect small ampullary carcinoma.
Geier A; Nguyen HN; Gartung C; Matern S
Lancet; 2000 Nov; 356(9241):1607-8. PubMed ID: 11075797
[No Abstract] [Full Text] [Related]
16. Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry.
Kumari N; Prabha K; Singh RK; Baitha DK; Krishnani N
Hum Pathol; 2013 Oct; 44(10):2213-9. PubMed ID: 23834763
[TBL] [Abstract][Full Text] [Related]
17. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
[No Abstract] [Full Text] [Related]
18. Pathologic Subtypes of Ampullary Adenocarcinoma: Value of Ampullary MDCT for Noninvasive Preoperative Differentiation.
Ivanovic AM; Alessandrino F; Maksimovic R; Micev M; Ostojic S; Gore RM; Mortele KJ
AJR Am J Roentgenol; 2017 Mar; 208(3):W71-W78. PubMed ID: 28095024
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
Okano K; Oshima M; Yachida S; Kushida Y; Kato K; Kamada H; Wato M; Nishihira T; Fukuda Y; Maeba T; Inoue H; Masaki T; Suzuki Y
J Surg Oncol; 2014 Aug; 110(2):156-62. PubMed ID: 24619853
[TBL] [Abstract][Full Text] [Related]
20. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
